amodiaquine has been researched along with Vomiting in 6 studies
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.
amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.
Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Artemether-lumefantrine plus amodiaquine provides an alternative to artemether-lumefantrine alone as first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion, and could prolong the therapeutic lifetime of artemether-lumefantrine in malaria-endemic populations." | 9.51 | Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. ( Amaratunga, C; Callery, JJ; Chau, NH; Chotivanich, K; Chotsiri, P; Day, NPJ; Dhorda, M; Dondorp, AM; Duanguppama, J; Dung, NTP; Hien, TT; Hoglund, RM; Imwong, M; Lek, D; Long, LT; Maude, RJ; Miotto, O; Mukaka, M; Nghia, HDT; Nguon, C; Peto, TJ; Rekol, H; Ruecker, A; Sokha, M; Sovann, Y; Tarning, J; Thuong, NTH; Tripura, R; van der Pluijm, RW; Van Luong, V; von Seidlein, L; Waithira, N; White, NJ, 2022) |
| "Artemether-lumefantrine plus amodiaquine provides an alternative to artemether-lumefantrine alone as first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion, and could prolong the therapeutic lifetime of artemether-lumefantrine in malaria-endemic populations." | 5.51 | Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. ( Amaratunga, C; Callery, JJ; Chau, NH; Chotivanich, K; Chotsiri, P; Day, NPJ; Dhorda, M; Dondorp, AM; Duanguppama, J; Dung, NTP; Hien, TT; Hoglund, RM; Imwong, M; Lek, D; Long, LT; Maude, RJ; Miotto, O; Mukaka, M; Nghia, HDT; Nguon, C; Peto, TJ; Rekol, H; Ruecker, A; Sokha, M; Sovann, Y; Tarning, J; Thuong, NTH; Tripura, R; van der Pluijm, RW; Van Luong, V; von Seidlein, L; Waithira, N; White, NJ, 2022) |
| "Seven patients developed hepatitis after receiving amodiaquine for malaria prophylaxis for 4 to 15 weeks." | 3.67 | Amodiaquine-induced hepatitis. A report of seven cases. ( Benhamou, JP; Castot, A; Feldmann, G; Larrey, D; Lenoir, A; Machayekhy, JP; Merigot, P; Pëssayre, D; Rueff, B, 1986) |
| "Methylene blue (MB) was the first synthetic antimalarial drug ever used, and recent studies have been promising with regard to its revival in malaria therapy." | 2.73 | Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. ( Coulibaly, B; Klose, C; Kouyaté, B; Mansmann, U; Meissner, P; Mockenhaupt, FP; Müller, O; Schirmer, RH; Sié, A; Walter-Sack, I; Zoungrana, A, 2008) |
| " No significant adverse event attributable to any of the study drugs was found." | 2.73 | Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. ( Dama, S; Dembele, D; Dicko, A; Djimdé, AA; Doumbo, OK; Fofana, B; Ouologuem, D; Sagara, I; Sidibe, B; Toure, S, 2008) |
| "Vomiting was more frequent in the artesunate + amodiaquine on D1 and D2." | 1.32 | [Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi]. ( Barihuta, T; Barutwanayo, M; Bosman, A; Ciza, A; Delacollette, C; Kamana, J; Karenzo, J; Mizero, L; Moyou-Somo, R; Nahimana, A; Ndaruhutse, J; Ndayiragije, A; Niyungeko, D; Niyungeko, E; Nyarushatsi, JP; Ringwald, P, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Peto, TJ | 1 |
| Tripura, R | 1 |
| Callery, JJ | 1 |
| Lek, D | 1 |
| Nghia, HDT | 1 |
| Nguon, C | 1 |
| Thuong, NTH | 1 |
| van der Pluijm, RW | 1 |
| Dung, NTP | 1 |
| Sokha, M | 1 |
| Van Luong, V | 1 |
| Long, LT | 1 |
| Sovann, Y | 1 |
| Duanguppama, J | 1 |
| Waithira, N | 1 |
| Hoglund, RM | 1 |
| Chotsiri, P | 1 |
| Chau, NH | 1 |
| Ruecker, A | 1 |
| Amaratunga, C | 1 |
| Dhorda, M | 1 |
| Miotto, O | 1 |
| Maude, RJ | 1 |
| Rekol, H | 1 |
| Chotivanich, K | 1 |
| Tarning, J | 1 |
| von Seidlein, L | 1 |
| Imwong, M | 1 |
| Mukaka, M | 1 |
| Day, NPJ | 1 |
| Hien, TT | 1 |
| White, NJ | 1 |
| Dondorp, AM | 1 |
| Ndayiragije, A | 1 |
| Niyungeko, D | 1 |
| Karenzo, J | 1 |
| Niyungeko, E | 1 |
| Barutwanayo, M | 1 |
| Ciza, A | 1 |
| Bosman, A | 1 |
| Moyou-Somo, R | 1 |
| Nahimana, A | 1 |
| Nyarushatsi, JP | 1 |
| Barihuta, T | 1 |
| Mizero, L | 1 |
| Ndaruhutse, J | 1 |
| Delacollette, C | 1 |
| Ringwald, P | 1 |
| Kamana, J | 1 |
| Zoungrana, A | 1 |
| Coulibaly, B | 1 |
| Sié, A | 1 |
| Walter-Sack, I | 1 |
| Mockenhaupt, FP | 1 |
| Kouyaté, B | 1 |
| Schirmer, RH | 1 |
| Klose, C | 1 |
| Mansmann, U | 1 |
| Meissner, P | 1 |
| Müller, O | 1 |
| Djimdé, AA | 1 |
| Fofana, B | 1 |
| Sagara, I | 1 |
| Sidibe, B | 1 |
| Toure, S | 1 |
| Dembele, D | 1 |
| Dama, S | 1 |
| Ouologuem, D | 1 |
| Dicko, A | 1 |
| Doumbo, OK | 1 |
| Talani, P | 1 |
| Samba, G | 1 |
| Moyen, G | 1 |
| Larrey, D | 1 |
| Castot, A | 1 |
| Pëssayre, D | 1 |
| Merigot, P | 1 |
| Machayekhy, JP | 1 |
| Feldmann, G | 1 |
| Lenoir, A | 1 |
| Rueff, B | 1 |
| Benhamou, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of the Triple ACT Artemether-lumefantrine+Amodiaquine (AL+AQ) Compared to the ACT Artemether-lumefantrine (AL) in Uncomplicated Falciparum Malaria in Cambodia and [NCT03355664] | Phase 3 | 310 participants (Actual) | Interventional | 2018-03-19 | Completed | ||
| [NCT00354380] | Phase 2 | 0 participants | Interventional | 2006-09-30 | Completed | ||
| A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined[NCT03143218] | Phase 3 | 5,920 participants (Actual) | Interventional | 2017-04-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The time taken for the tympanic temperature to fall below 37.5˚C and remain there for at least 24 hours (NCT03355664)
Timeframe: 42 day
| Intervention | Hours to fever clearance (Mean) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 18.3 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 14.9 |
Total bilirubin, Alanine transaminase, Aspartate transaminase, Alkaline phosphatase and creatinine will be measured (NCT03355664)
Timeframe: 42 day
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 53 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 63 |
We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater. (NCT03355664)
Timeframe: 28 day
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 0 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 0 |
"All numerators in AE tables mean that the AE was reported as present according to the definitions defined in the US government DAIDS 2017 grading tables for reporting of adverse events. The AEs are reported without grading in this table, but are graded in the paper reporting this clinical trial.~All Primary analyses are reported (also in the accepted manuscript) along with the secondary outcomes needed to support the primary analysis. Secondary outcomes not involving the randomised comparison will be updated when the analyses are available. Please note that analyses of these Secondary outcomes will take time." (NCT03355664)
Timeframe: 42 days
| Intervention | Participants (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 2 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 5 |
Parasite clearance half-life assessed by microscopy as primary parameter to determine parasite clearance (NCT03355664)
Timeframe: 42 day
| Intervention | Hours (Mean) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 5 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 5.5 |
Efficacy is defined as participants, following initial parasite and fever clearance, not having a recrudescence of the original plasmodium infection and fever, up to 42 days of follow up. (NCT03355664)
Timeframe: 42 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 146 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 151 |
We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater. There were zero events of this at any time point in either study arm. So no further analyses are possible. (NCT03355664)
Timeframe: Hour 4, Hour 24, Hour 28, Hour 48, Hour 52, Hour 60, Hour 64, Day 7 and Day 28 and between these time points
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 0 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 0 |
42-day polymerase chain reaction corrected efficacy defined as adequate clinical and parasitological response (ACPR) according to site/geographic region. (NCT03355664)
Timeframe: 42 day
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| West Cambodia | East Cambodia | Vietnam | |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 35 | 90 | 26 |
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 32 | 91 | 23 |
Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more (NCT03143218)
Timeframe: Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.
| Intervention | No. of events/1000 person years at risk (Number) |
|---|---|
| SMC With SP+AQ | 304.8 |
| RTS,S/AS01 | 278.2 |
| RTS,S/AS01 PLUS SMC With SP+AQ | 113.3 |
3 trials available for amodiaquine and Vomiting
| Article | Year |
|---|---|
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Dru | 2022 |
Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Topics: Amodiaquine; Artemisinins; Artesunate; Burkina Faso; Drug Therapy, Combination; Drug-Related Side Ef | 2008 |
Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Biomarkers; Drug Combinations; Drug R | 2008 |
3 other studies available for amodiaquine and Vomiting
| Article | Year |
|---|---|
[Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi].
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Burundi; Child, Preschool; Drug Re | 2004 |
[Management of child fever in the battle against malaria in Brazzaville].
Topics: Amodiaquine; Antimalarials; Asthenia; Child, Preschool; Chills; Chloroquine; Congo; Diarrhea; Fever; | 2002 |
Amodiaquine-induced hepatitis. A report of seven cases.
Topics: Adult; Alanine Transaminase; Amodiaquine; Aspartate Aminotransferases; Asthenia; Chemical and Drug I | 1986 |